资讯

MyChesCo on MSN21 小时
Arbutus Biopharma Reports Q1 2025 Results, Clinical Developments, and Legal Progress
Arbutus Biopharma Corporation (Nasdaq: ABUS), a key player in advancing treatments for chronic hepatitis B (cHBV), outlined ...